CVPath Leadership address CRT20 Conference
February 26, 2020
Dr. Virmani, President, and Dr. Finn, Medical Director, of CVPath Institute recently presented at CRT20 held February 22-25 at the Gaylord National Convention Center at the National Harbor, Maryland. Dr. Virmani spoke on the Differences in Atherosclerosis in Different Beds at Sunday’s session Insights into the Pathophysiology and Mechanisms of Atherosclerotic Disease and on What Should be the Safety Profile of Drug-Eluting Stents Suitable for Short DAPT at the Monday evening session on Optimizing Stent, Antiplatelet and Techniques Choice for Complex Patients with Complex Lesions: Update on the Onyx One Study and Relevance for Clinical Practice.
Dr. Finn presented at several sessions on the following topics: Cholesterol Crystals: Does Medical Therapy Dissolve the Crystals in the Coronary Plaque? at the Sunday morning sessions Novel Therapies for the Treatment of the Vulnerable Plaque; Science and Myths Behind Device-Based Technology Hypertension Definition, Pathophysiology, New Targets and Medical Therapy. On Monday morning he spoke on What Are the Pathological Concerns and Limitations of Current DCB Technology? at the DCB Technology Symposium and What Are the Challenges for Sirolimus Coated Balloons – Will They Work as PTX DCB? at the session on DCB for Coronary Applications.
Additionally, CVPath Institute staff pathologists, Bob Kutys and Nicole Singer supported Live Hearts, an anatomic heart disease session where participants get hands-on instruction with autopsy hearts emphasizing valve and congenital disease.
CRT, one of the world’s leading interventional cardiology conferences, is held annually in the Washington, DC metropolitan area, is supported by MedStar Health & the MedStar Heart & Vascular Institute and serves as a forum for physician and health-care professional education about new cardiovascular technology and interventional procedures in the field. The meeting is actually several conferences at once, with tracks including CRT Valve & Structural, CRT Endovascular, Technology & Innovation, Atherosclerosis & Research, and Nurses & Technologists. It is attended by more than 3,000 interventional and endovascular specialists.